Supporting these findings, NF-κB1 sequencing informs liver function assessment [29], NFE2L2 activators counter hepatic lipotoxicity [30], and SERPINE1 serves as a biomarker in fatty liver disease and renal cancer progression [31,32]. The gene discussed is NFE2L2; the disease is renal carcinoma.